Is Arno Therapeutics, Inc. (ARNI) a Buy, Sell, or Hold?
OTC : ARNI
Arno Therapeutics, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 800
- Average Volume
- 40
- Market Capitalization
- $4.94K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.08
Company Overview
OTC
David M. Tanen
Biotechnology
Healthcare
ARNI
4
US
USD
Liquidity Metrics
-0.24
0.08
0.08
0.02
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-0.49
Profitability
-$0.57
-$11.54M
0.00%
0.00%
250.44%
-3193.55%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-76.93
2/9
$799.99K
$2.36M
$8.07M
-$11.51M
Key Metrics (TTM)
$2.04M
0.00
-0.15
0.08
250.44%
755.35%
-565269.39%
-201937.14%
-48345 days
Company Executives
| Name | Title |
|---|---|
| David Tanen | Sec. |
Poll Results
No votes yet today — be the first to share your view!
About Arno Therapeutics, Inc. (OTC:ARNI) Stock
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potentia ... l applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Frequently Asked Questions
-
What is the current Arno Therapeutics, Inc. (ARNI) stock price?
-
Arno Therapeutics, Inc.(OTC:ARNI) stock price is $0.0001 in the last trading session. During the trading session, ARNI stock reached the peak price of $0.0002 while $0.0001 was the lowest point it dropped to. The percentage change in ARNI stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARNI stock was $0.
-
ARNI's industry and sector of operation?
-
The OTC listed ARNI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ARNI?
-
David Tanen | Sec.
|
|
|
| -
How many employees does ARNI have?
-
Number of ARNI employees currently stands at 4. ARNI operates from 200 Route 31 North, Flemington, NJ 08822, US.
-
Link for ARNI official website?
-
Official Website of ARNI is: https://www.arnothera.com
-
How do I contact ARNI?
-
ARNI could be contacted at phone #862 703 7170 and can also be accessed through its website. ARNI operates from 200 Route 31 North, Flemington, NJ 08822, US.
-
How many shares of ARNI are traded daily?
-
The average number of ARNI shares traded daily for last 3 months was 40.
-
What is the market cap of ARNI currently?
-
The market value of ARNI currently stands at $4.94K with its latest stock price at $0.0001